Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

Guy W. Neff; Marzia Montalbano; Christopher B. O'Brien; Seigo Nishida; Kamran Safdar; Pablo A. Bejarano; Amr S. Khaled; Phillip Ruiz; Gabriella Slapak-Green; Mei Lee; Jose Nery; Maria De Medina; Andreas Tzakis; Eugene R. Schiff

doi:10.1097/01.TP.0000129811.93072.1C

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

Guy W. Neff, Marzia Montalbano, Christopher B. O'Brien, Seigo Nishida, Kamran Safdar, Pablo A. Bejarano, Amr S. Khaled, Phillip Ruiz, Gabriella Slapak-Green, Mei Lee, Jose Nery, Maria De Medina, Andreas Tzakis, Eugene R. Schiff

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction. The management issues of transplant patients with hepatitis C virus (HCV) are complex, and interferon therapy is often ineffective. We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin. Methods. A retrospective review of transplant recipients that received combination pegylated alpha-2b interferon (1.5 mcg/kg/wk) and ribavirin (400-600 mg/day) therapy intended for at least 48 weeks. Complications were recorded and included neutropenia (

Original language	English
Pages (from-to)	1303-1307
Number of pages	5
Journal	Transplantation
Volume	78
Issue number	9
DOIs	https://doi.org/10.1097/01.TP.0000129811.93072.1C
Publication status	Published - Nov 15 2004

Keywords

Fulminant hepatic failure
Hepatitis B virus
Hepatitis C virus
Interferon
Orthotopic liver transplantation

ASJC Scopus subject areas

Transplantation
Immunology

Access to Document

10.1097/01.TP.0000129811.93072.1C

Cite this

Neff, G. W., Montalbano, M., O'Brien, C. B., Nishida, S., Safdar, K., Bejarano, P. A., Khaled, A. S., Ruiz, P., Slapak-Green, G., Lee, M., Nery, J., De Medina, M., Tzakis, A., & Schiff, E. R. (2004). Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation, 78(9), 1303-1307. https://doi.org/10.1097/01.TP.0000129811.93072.1C

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. / Neff, Guy W.; Montalbano, Marzia; O'Brien, Christopher B.; Nishida, Seigo; Safdar, Kamran; Bejarano, Pablo A.; Khaled, Amr S.; Ruiz, Phillip; Slapak-Green, Gabriella; Lee, Mei; Nery, Jose; De Medina, Maria; Tzakis, Andreas; Schiff, Eugene R.

In: Transplantation, Vol. 78, No. 9, 15.11.2004, p. 1303-1307.

Research output: Contribution to journal › Article › peer-review

Neff, GW, Montalbano, M, O'Brien, CB, Nishida, S, Safdar, K, Bejarano, PA, Khaled, AS, Ruiz, P, Slapak-Green, G, Lee, M, Nery, J, De Medina, M, Tzakis, A & Schiff, ER 2004, 'Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy', Transplantation, vol. 78, no. 9, pp. 1303-1307. https://doi.org/10.1097/01.TP.0000129811.93072.1C

Neff, Guy W. ; Montalbano, Marzia ; O'Brien, Christopher B. ; Nishida, Seigo ; Safdar, Kamran ; Bejarano, Pablo A. ; Khaled, Amr S. ; Ruiz, Phillip ; Slapak-Green, Gabriella ; Lee, Mei ; Nery, Jose ; De Medina, Maria ; Tzakis, Andreas ; Schiff, Eugene R. / Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. In: Transplantation. 2004 ; Vol. 78, No. 9. pp. 1303-1307.

@article{51a9cdcc8dd9480184b5edd793284dad,

title = "Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy",

abstract = "Introduction. The management issues of transplant patients with hepatitis C virus (HCV) are complex, and interferon therapy is often ineffective. We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin. Methods. A retrospective review of transplant recipients that received combination pegylated alpha-2b interferon (1.5 mcg/kg/wk) and ribavirin (400-600 mg/day) therapy intended for at least 48 weeks. Complications were recorded and included neutropenia (",

keywords = "Fulminant hepatic failure, Hepatitis B virus, Hepatitis C virus, Interferon, Orthotopic liver transplantation",

author = "Neff, {Guy W.} and Marzia Montalbano and O'Brien, {Christopher B.} and Seigo Nishida and Kamran Safdar and Bejarano, {Pablo A.} and Khaled, {Amr S.} and Phillip Ruiz and Gabriella Slapak-Green and Mei Lee and Jose Nery and {De Medina}, Maria and Andreas Tzakis and Schiff, {Eugene R.}",

year = "2004",

month = nov,

day = "15",

doi = "10.1097/01.TP.0000129811.93072.1C",

language = "English",

volume = "78",

pages = "1303--1307",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

AU - Neff, Guy W.

AU - Montalbano, Marzia

AU - O'Brien, Christopher B.

AU - Nishida, Seigo

AU - Safdar, Kamran

AU - Bejarano, Pablo A.

AU - Khaled, Amr S.

AU - Ruiz, Phillip

AU - Slapak-Green, Gabriella

AU - Lee, Mei

AU - Nery, Jose

AU - De Medina, Maria

AU - Tzakis, Andreas

AU - Schiff, Eugene R.

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Introduction. The management issues of transplant patients with hepatitis C virus (HCV) are complex, and interferon therapy is often ineffective. We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin. Methods. A retrospective review of transplant recipients that received combination pegylated alpha-2b interferon (1.5 mcg/kg/wk) and ribavirin (400-600 mg/day) therapy intended for at least 48 weeks. Complications were recorded and included neutropenia (

AB - Introduction. The management issues of transplant patients with hepatitis C virus (HCV) are complex, and interferon therapy is often ineffective. We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin. Methods. A retrospective review of transplant recipients that received combination pegylated alpha-2b interferon (1.5 mcg/kg/wk) and ribavirin (400-600 mg/day) therapy intended for at least 48 weeks. Complications were recorded and included neutropenia (

KW - Fulminant hepatic failure

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - Interferon

KW - Orthotopic liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=8644285360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644285360&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000129811.93072.1C

DO - 10.1097/01.TP.0000129811.93072.1C

M3 - Article

C2 - 15548967

AN - SCOPUS:8644285360

VL - 78

SP - 1303

EP - 1307

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this